European breast cancer therapeutics market is estimated to grow significantly at a CAGR of around 8.8% during the forecast period. The market is mainly driven due to the high prevalence of breast cancer within European countries that include UK, Germany, Italy Spain and others. These countries play a significant role in growth including awareness programs, the introduction of new treatment solutions and government expenditure on breast cancer diagnosis and treatment. The European Breast Cancer Coalition works to raise awareness of breast cancer. The European Commission launched European Commission Initiative on Breast Cancer (ECIBC) in 2012 to ensure that all breast cancer care processes are performed with quality and correctly in all citizens in Europe.

European breast cancer therapeutics market is segmented on the basis of therapy. The Therapy segment is further classified into chemotherapy, hormone therapy, targeted therapy, radiation therapy and others (surgery). Among all therapies, chemotherapy market held the largest market share in the European breast cancer therapeutics market. Chemotherapy is most used when cancer in the lymph nodes and irrespective of tumor size or menopausal status. Along with that it is used for the treatment of breast cancer in premenopausal women and referred for those women who diagnosed with early stage breast cancer for hormone receptor negative and HER2 positive cancer. The types of chemotherapy include adjuvant chemotherapy and neoadjuvant chemotherapy. The adjuvant chemotherapy is used to destroy cancer cells that have been spread and not seen by the imaging tests. This method helps in reducing the cancer cells that form a new tumor in the other place of the body. Adjuvant chemotherapy reduces the risk of breast cancer coming back. Neoadjuvant chemotherapy can be used to reduce the size of the tumor, so it can be removed with less widespread surgery. 

The companies which are contributing to the growth of the European breast cancer therapeutics market include AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Mylan NV, Novartis International AG, F. Hoffmann-La Roche AG, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the European breast cancer therapeutics market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

Market Segmentation

1. European breast cancer Therapeutics Market Research and Analysis by Therapy

The Report Covers

• Comprehensive research methodology of the European breast cancer therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European breast cancer therapeutics market.
• Insights about market determinants which are stimulating the European breast cancer therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.